Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CHL
MCID: LYM133
MIFTS: 69

Lymphoma, Hodgkin, Classic (CHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma, Hodgkin, Classic

About this section

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

Name: Lymphoma, Hodgkin, Classic 56 73 37 39
Hodgkin Lymphoma 56 12 74 52 58 36 29 13 6 15 32
Hodgkin Disease 56 12 52 73 54 42 71
Hodgkin's Lymphoma 12 52 15
Hodgkins Lymphoma 12 17
Chl 56 73
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 71
Hodgkin's Disease of Intrapelvic Lymph Nodes 71
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Susceptibility to 39
Hodgkin Lymphoma, Susceptibility to 56
Classic Hodgkin Lymphoma 58
Classic Hodgkin Disease 58
Lymphoma, Hodgkin's 52
Hodgkin's Sarcoma 12
Hodgkin's Disease 74
Hl 12

Characteristics:

Orphanet epidemiological data:

58
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;
hodgkin lymphoma
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: Adult;

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
lymphoma, hodgkin, classic:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


Sources

Summaries for Lymphoma, Hodgkin, Classic

About this section
NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 98293 Definition Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. Epidemiology HL is an uncommon cancer with an incidence of about 1/40,000 in North America and Europe. There are about 8500 new cases reported in the U.S. each year. Clinical description HL is comprised of 2 major forms: classical Hodgkin lymphoma (CHL; see this term), seen in 95% of all HL cases, and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL; see this term), seen in only 5% of all HL cases. Disease onset occurs most frequently in young adults (age 15-35) followed by older adults (over the age of 55) and usually begins with the painless swelling of a lymph node in the upper body. Disease can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients. Etiology The exact cause is unknown but immunological, genetic and environmental factors are thought to be involved. Management and treatment Treatment with radiotherapy and systemic chemotherapy leads to a very good prognosis . Follow-up physical exams, blood tests and x-rays are needed to check for recurrence and check for any long-term side effects of the toxic treatments. Possible long-term side effects include secondary cancers, infertility, reduced immunity, thyroid problems, heart disease and stroke. Prognosis The international prognostic score (IPS) is a score given based on the presence of 7 risk factors (male sex, >45 years of age, stage 4 disease, serum albumin <4g/dl, hemoglobin <10.5 g/l, lymphocytopenia and WBC count >15,000/mm3) at the time of diagnosis. The more factors present, the less favorable the prognosis. The cure rates are 90% for early-stage HL and 70% for advance stage HL. Visit the Orphanet disease page for more resources.

MalaCards based summary : Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to nodular lymphocyte predominant hodgkin lymphoma and hodgkin's lymphoma, lymphocytic depletion. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Viral carcinogenesis. The drugs Angiotensin II and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are fatigue and immunodeficiency

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

OMIM : 56 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000)

MedlinePlus : 42 Hodgkin disease is a type of lymphoma. Lymphoma is a cancer of a part of the immune system called the lymph system. The first sign of Hodgkin disease is often an enlarged lymph node. The disease can spread to nearby lymph nodes. Later it may spread to the lungs, liver, or bone marrow. The exact cause is unknown. Hodgkin disease is rare. Symptoms include Painless swelling of the lymph nodes in the neck, armpits, or groin Fever and chills Night sweats Weight loss Loss of appetite Itchy skin To diagnose Hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. Treatment depends on how far the disease has spread. It often includes radiation therapy or chemotherapy. The earlier the disease is diagnosed, the more effective the treatment. In most cases, Hodgkin disease can be cured. NIH: National Cancer Institute

KEGG : 36 Hodgkin's lymphoma (HL) is one of the most frequent lymphomas in the Western world and often affects young adults. HL is subdivided into classical and nodular lymphocyte-predominant forms. About 95% of cases are classical HL, and 5% are nodular lymphocyte-predominant HL (NLPHL). A characteristic feature of HL is the rareness of the tumor cells, which are called Hodgkin's and Reed/Sternberg (HRS) cells in classical HL and lymphocytic and histiocytic (L&H) cells in NLPHL. These cells represent only about 1% of the cellular infiltrate, while the vast majority of infiltrating cells are T lymphocytes, histiocytes, eosinophilic granulocytes and plasma cells. HRS cells show constitutive activity of both the classical and alternative NF-{kappa}B signalling pathways, which is probably a major pathogenetic mechanism in Hodgkin's lymphoma. The NF-{kappa}B activity in HRS cells is probably mediated by diverse mechanisms: receptor signalling through CD40, RANK, BCMA, and TACI, genomic REL amplification, destructive mutations in IKBA and IKBE. In HL pathogenesis associated with Epstein-Barr virus infection, the activation of NF-{kappa}B is induced by viral latent membrane protein 1 (LMP1).

UniProtKB/Swiss-Prot : 73 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Wikipedia : 74 Hodgkin lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white... more...

Sources

Related Diseases for Lymphoma, Hodgkin, Classic

About this section

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1964)
# Related Disease Score Top Affiliating Genes
1 nodular lymphocyte predominant hodgkin lymphoma 35.0 TNFRSF8 PAX5 BCL6
2 hodgkin's lymphoma, lymphocytic depletion 34.2 TNFRSF8 PAX5
3 hodgkin's lymphoma, nodular sclerosis 34.1 TNFRSF8 PAX5 KLHDC8B BCL6
4 hodgkin's lymphoma, lymphocytic-histiocytic predominance 33.7 TNFRSF8 BCL6
5 t-cell/histiocyte rich large b cell lymphoma 33.7 TNFRSF8 BCL6
6 lymphoma, mucosa-associated lymphoid type 33.6 TNFRSF8 PAX5 IRF4 BCL6
7 mantle cell lymphoma 33.5 PAX5 MIR155 CSF3 BCL6
8 t-cell lymphoma, subcutaneous panniculitis-like 33.5 TNFRSF8 ALK
9 primary central nervous system lymphoma 33.4 PAX5 BCL6
10 mediastinal gray zone lymphoma 33.4 TNFRSF8 PAX5
11 reticulosarcoma 33.4 TNFRSF8 PAX5 BCL6 ALK
12 gray zone lymphoma 33.4 TNFRSF8 PAX5 BCL6
13 intraocular lymphoma 33.2 PAX5 BCL6
14 primary mediastinal large b-cell lymphoma 32.6 IRF4 BCL6
15 marginal zone b-cell lymphoma 32.1 TNFRSF8 PAX5 IRF4 BCL6
16 lymphoblastic lymphoma 31.9 TNFRSF8 PAX5 BCL6
17 peripheral t-cell lymphoma 31.8 TNFRSF8 PAX5 BCL6 ALK
18 testicular lymphoma 31.4 TNFRSF8 IRF4 BCL6
19 mediastinal malignant lymphoma 31.4 TNFRSF8 PAX5
20 dermatomyositis 31.4 MIR30A MIR21 MIR155
21 skin carcinoma 31.4 MIR30A MIR21 MIR140 CSF3
22 polymyositis 31.3 MIR30A MIR21 MIR155
23 bone lymphoma 31.3 TNFRSF8 PAX5 IRF4 BCL6 ALK
24 myeloma, multiple 31.3 TNFRSF8 PVT1 PAX5 MIR30A MIR21 MIR186
25 breast lymphoma 31.3 TNFRSF8 PAX5 IRF4 BCL6 ALK
26 renal cell carcinoma, nonpapillary 31.2 PVT1 MIR30B MIR30A MIR21 MIR200A MIR18A
27 plasmacytoma 31.2 PVT1 PAX5 IRF4
28 pediatric lymphoma 31.2 TNFRSF8 IRF4 BCL6 ALK
29 adult lymphoma 31.1 TNFRSF8 IRF4 CSF3 BCL6 ALK
30 arteries, anomalies of 31.0 MIR30B MIR30A MIR21 MIR18A MIR155 MIR140
31 primary cutaneous anaplastic large cell lymphoma 31.0 IRF4 ALK
32 multicentric castleman disease 31.0 PAX5 IRF4 BCL6
33 lung lymphoma 31.0 TNFRSF8 PAX5 BCL6
34 central nervous system disease 30.9 MIR30B MIR30A MIR21 MIR18A MIR155 MIR140
35 lymphomatoid papulosis 30.9 TNFRSF8 ALK
36 plasma cell neoplasm 30.9 PVT1 PAX5 IRF4 BCL6
37 anaplastic large cell lymphoma 30.9 TNFRSF8 PAX5 IRF4 ALK
38 esophageal cancer 30.8 PVT1 MIR30A MIR21 MIR200A MIR155 MIR140
39 connective tissue disease 30.8 MIR30B MIR30A MIR21 MIR18A MIR155 MIR140
40 follicular lymphoma 30.8 PAX5 MIR155 IRF4 BCL6
41 nervous system disease 30.7 MIR30B MIR30A MIR21 MIR20A MIR200A MIR18A
42 cervical cancer 30.7 PVT1 MIR30A MIR21 MIR20A MIR200A MIR186
43 breast implant-associated anaplastic large cell lymphoma 30.6 TNFRSF8 ALK
44 lymphoma 30.6 TNFRSF8 PVT1 PAX5 KLHDC8B IRF4 CSF3
45 heart lymphoma 30.6 BCL6 ALK
46 paranasal sinus lymphoma 30.6 TNFRSF8 PAX5 BCL6
47 autoimmune lymphoproliferative syndrome, type v 30.6 TNFRSF8 BCL6 ALK
48 tracheal lymphoma 30.6 TNFRSF8 PAX5 BCL6
49 adult acute lymphocytic leukemia 30.6 TNFRSF8 PAX5 CSF3
50 b-cell lymphoma 30.6 TNFRSF8 PVT1 PAX5 MIR21 MIR20A MIR155

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:



Diseases related to Lymphoma, Hodgkin, Classic
Sources

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

About this section

Human phenotypes related to Lymphoma, Hodgkin, Classic:

58 31 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012378
2 immunodeficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0002721
3 cellular immunodeficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0005374
4 lymphoma 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002665
5 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0002716
6 fever 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0001945
7 hyperhidrosis 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000975
8 weight loss 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0001824
9 pruritus 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000989
10 cough 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0012735
11 chest pain 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0100749
12 anorexia 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0002039
13 poor appetite 58 31 frequent (33%) Frequent (79-30%) HP:0004396
14 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001744
15 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002240
16 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
17 ataxia 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001251
18 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0009830
19 skin rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0000988
20 osteolysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002797
21 respiratory insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002093
22 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002105
23 migraine 58 31 occasional (7.5%) Occasional (29-5%) HP:0002076
24 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
25 bone pain 58 31 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002653
26 bone marrow hypocellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0005528
27 neoplasm 58 Occasional (29-5%),Occasional (29-5%)
28 abnormality of blood and blood-forming tissues 58 Occasional (29-5%)
29 hodgkin lymphoma 31 HP:0012189
30 polyclonal elevation of igm 31 HP:0003459
31 impaired lymphocyte transformation with phytohemagglutinin 31 HP:0003347

Symptoms via clinical synopsis from OMIM:

56
Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease

Clinical features from OMIM:

236000
Sources

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

About this section

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 592)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
7
Prilocaine Approved Phase 4 721-50-6 4906
8
Clarithromycin Approved Phase 4 81103-11-9 84029
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Ribavirin Approved Phase 4 36791-04-5 37542
11
Fotemustine Investigational Phase 4 92118-27-9
12
Pirarubicin Investigational Phase 4 72496-41-4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Anesthetics, General Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Angiotensinogen Phase 4
17 Antihypertensive Agents Phase 4
18 Anti-Arrhythmia Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Proton Pump Inhibitors Phase 4
22 Angiotensin II Type 1 Receptor Blockers Phase 4
23 Angiotensin Receptor Antagonists Phase 4
24 Giapreza Phase 4
25 Sodium Channel Blockers Phase 4
26 Diuretics, Potassium Sparing Phase 4
27 Anesthetics, Inhalation Phase 4
28 Lidocaine, Prilocaine Drug Combination Phase 4
29 Hematinics Phase 4
30 Epoetin alfa Phase 4 113427-24-0
31
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
32
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
33
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
34
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
35
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
36
Adenosine Approved, Investigational Phase 3 58-61-7 60961
37
Pentostatin Approved, Investigational Phase 3 53910-25-1 439693 40926
38
Tazobactam Approved Phase 3 89786-04-9 123630
39
Vancomycin Approved Phase 3 1404-90-6 14969 441141
40
Piperacillin Approved Phase 3 66258-76-2 43672
41
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
42
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
43
deoxycholic acid Approved Phase 3 83-44-3 222528
44
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
46
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
47
Dalteparin Approved Phase 3 9005-49-6
48
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
49
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
50
Morphine Approved, Investigational Phase 3 57-27-2 5288826

Interventional clinical trials:

(show top 50) (show all 3012)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
5 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
6 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
7 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
8 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
9 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
10 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
11 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
12 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
13 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
14 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
15 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
16 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
17 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
18 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
19 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;Livopan;EMLA
21 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
22 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
23 The Effect of Special Diets on Weight and Nutritional Intake in Haematological Cancer Patients Completed NCT02880709 Phase 4
24 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
25 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
26 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
27 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
28 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
29 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
30 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
31 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Not yet recruiting NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
32 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
33 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
34 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
35 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
36 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
37 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
38 Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
39 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
40 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
41 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
42 Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups Unknown status NCT00005584 Phase 3 ABVD regimen;BEACOPP regimen;epirubicin hydrochloride;prednisone;vinblastine sulfate
43 A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
44 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
45 Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission Unknown status NCT00091676 Phase 3
46 Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial] Unknown status NCT00379041 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
47 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
48 Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
49 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
50 A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL Unknown status NCT00129090 Phase 3 R-CHOEP 14 with 12x Rituximab

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Lymphoma, Hodgkin, Classic:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Peripheral blood stem cells for treatment of hematologic malignancies
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Embryonic/Adult Cultured Cells Related to Lymphoma, Hodgkin, Classic:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Sources

Genetic Tests for Lymphoma, Hodgkin, Classic

About this section

Genetic tests related to Lymphoma, Hodgkin, Classic:

# Genetic test Affiliating Genes
1 Hodgkin Lymphoma 29 KLHDC8B
Sources

Anatomical Context for Lymphoma, Hodgkin, Classic

About this section

MalaCards organs/tissues related to Lymphoma, Hodgkin, Classic:

40
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Breast, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
Sources

Publications for Lymphoma, Hodgkin, Classic

About this section

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 16961)
# Title Authors PMID Year
1
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. 56 6 61
19706467 2009
2
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. 61 54 56
17539776 2007
3
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. 61 54 56
11830502 2002
4
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. 61 56
21368758 2011
5
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. 54 56
20436485 2010
6
A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. 61 56
15994882 2005
7
Localization of predisposition to Hodgkin disease in the HLA class II region. 61 56
8116619 1994
8
A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis. 42 61
32481271 2020
9
Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. 42 61
32109715 2020
10
Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. 61 46
19775296 2009
11
Infection and lymphoma. 56
14523136 2003
12
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. 56
14523140 2003
13
Combined segregation and linkage analysis of 59 Hodgkin's disease families indicates the role of HLA determinants. 56
10878668 2000
14
A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. 56
10914686 2000
15
Familial Hodgkin's disease: a disease of young adulthood? 56
9111426 1997
16
Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. 56
7824015 1995
17
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. 56
8381153 1993
18
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. 56
1671232 1991
19
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. 56
2172169 1990
20
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. 56
2537928 1989
21
Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. 56
2536894 1989
22
Epstein-Barr viral DNA in tissues of Hodgkin's disease. 56
2821817 1987
23
HLA in familial Hodgkin's disease. 56
6875280 1983
24
Simultaneous Hodgkin's disease in three siblings with identical HLA-genotype. 56
7397649 1980
25
Infectious mononucleosis and Hodgkin's disease. 56
681023 1978
26
Serum genetic markers in a Newfoundland isolate with a familial aggregate of Hodgkin's disease. 56
680699 1978
27
HLA in familial Hodgkin's disease. Results and a new hypothesis;. 56
844915 1977
28
Hodgkin's disease in siblings. 56
831107 1977
29
Familial Hodgkin's disease and the major histocompatibility complex. 56
144365 1977
30
Familial Hodgkin's disease and associated cancer. A clinical-pathologic study. 56
991117 1976
31
Varied manifestations of a familial lymphoproliferative disorder. 56
806230 1975
32
Familial Hodgkin's disease: an environmental and genetic disorder. 56
4137662 1974
33
Family studies in Hodgkin's disease. 56
4842358 1974
34
Familial Hodgkin's disease. 56
4115609 1972
35
Mortality from Hodgkin's disease in the United States. Evidence for the multiple-aetiology hypothesis. 56
4177934 1968
36
Epidemiology of Hodgkin's disease. 56
5329907 1966
37
[FAMILIAL HODGKIN'S DISEASE]. 56
14154061 1964
38
Immune Thrombocytopenia Secondary to Hodgkin's Lymphoma in Children 42
32286024 2020
39
B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. 54 61
20398809 2010
40
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. 54 61
20065852 2010
41
Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. 54 61
20093237 2010
42
Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236. 61 54
19931589 2010
43
IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. 54 61
19804451 2010
44
IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. 54 61
19821826 2010
45
Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. 54 61
19550297 2010
46
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. 61 54
20093413 2010
47
Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. 54 61
19734449 2009
48
Low apoptotic index & bak expression in EBV-associated childhood classical Hodgkin lymphoma. 61 54
20090100 2009
49
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. 54 61
19666866 2009
50
STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. 54 61
19440213 2009
Sources

Variations for Lymphoma, Hodgkin, Classic

About this section

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KLHDC8B NM_173546.3(KLHDC8B):c.-158C>TSNV Pathogenic 273 rs387906223 3:49209095-49209095 3:49171662-49171662

Cosmic variations for Lymphoma, Hodgkin, Classic:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143780282 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 8

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

7 (show top 50) (show all 204)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma
Sources

Expression for Lymphoma, Hodgkin, Classic

About this section
Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.
Sources

Pathways for Lymphoma, Hodgkin, Classic

About this section

Pathways related to Lymphoma, Hodgkin, Classic according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 Viral carcinogenesis hsa05203
3 Epstein-Barr virus infection hsa05169

Pathways related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
11.97 TNFRSF8 PAX5 IRF4 BCL6
2
MicroRNAs in cancer 36
11.72 MIR520A MIR30B MIR30A MIR21 MIR20A MIR200A
3
Parkinsons Disease Pathway 1
11.06 MIR30A MIR20A MIR18A
Sources

GO Terms for Lymphoma, Hodgkin, Classic

About this section

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR374A MIR30B MIR30A MIR21 MIR20A MIR18A
2 extracellular vesicle GO:1903561 9.26 MIR30B MIR30A MIR21 MIR20A

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 MIR140 MIR155 MIR21 MIR30A MIR30B
2 cellular response to lipopolysaccharide GO:0071222 9.67 CSF3 MIR140 MIR20A MIR21
3 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.49 MIR140 MIR21
4 negative regulation of innate immune response GO:0045824 9.48 MIR155 MIR21
5 negative regulation of cell adhesion molecule production GO:0060354 9.46 MIR155 MIR20A
6 miRNA mediated inhibition of translation GO:0035278 9.46 MIR155 MIR20A MIR21 MIR30A
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR155 MIR20A
8 positive regulation of activated T cell proliferation GO:0042104 9.43 MIR155 MIR21 MIR30B
9 gene silencing by miRNA GO:0035195 9.36 MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A
10 positive regulation of vascular smooth muscle cell differentiation involved in phenotypic switching GO:1905932 9.32 MIR140 MIR18A
11 negative regulation of regulatory T cell differentiation GO:0045590 9.13 MIR155 MIR21 MIR30B

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR520A MIR30B MIR30A MIR21 MIR20A MIR200A
Sources

Sources for Lymphoma, Hodgkin, Classic

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....